Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
Pulmonary Disease, Chronic Obstructive, Asthma, Adverse Effect of Beta-adrenoreceptor Antagonists
About this trial
This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive focused on measuring Beta-Blocker, Chronic Obstructive Pulmonary Disease, COPD, Cardioselective
Eligibility Criteria
Inclusion Criteria:
- 40 years of age or older
- Mild to moderate COPD as defined by the American Thoracic Society
- Current treatment with a beta-blocker for either hypertension, myocardial infarction, or congestive heart failure.
Exclusion Criteria:
- Recent (within 30 days) COPD exacerbation or requirement for oral steroid therapy within the last 6 months
- Any history of ventilator support requirement for COPD
- Patients with asthma or reactive airway disease (RAD) defined as obstructive lung disease with a >15% improvement in FEV1 with beta-agonist therapy
- Relative or absolute contraindication to beta-blocker therapy
- Exposure to any investigational drugs within the previous 30 days
- Patients with any concurrent disease or condition, which in the judgment of the investigator would make the patient inappropriate for participation in the study were excluded from this study
Sites / Locations
- VA West Los Angeles Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Sequence 1
Sequence 2
Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10 Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18
Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10 Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18